NovoCure (NVCR) Non-Current Deferred Tax Liability (2018)
NovoCure (NVCR) posted quarterly Non-Current Deferred Tax Liability of $124000.0 for Q4 2018.
NovoCure (NVCR) Non-Current Deferred Tax Liability (2018) Analysis & Trends
NovoCure (NVCR) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $124000.0 the latest figure, recorded in Q4 2018.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $124000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $124000.0 (changed N/A YoY) and the FY2018 annual result came in at $124000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability held at $124000.0 in Q4 2018 per NVCR's latest filing.
- Over the last five years, Non-Current Deferred Tax Liability for NVCR reached as high as $124000.0 in Q4 2018 and fell as low as $124000.0 in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 124,000.00 |
| Dec 31, 2018 | 124,000.00 |